Alpha 2.0
Login Register
» Authors » Luk Corluy

Luk Corluy

Explore the profile of Luk Corluy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 93
Followers 0
Related Specialties
Rheumatology
Physiology
Orthopedics
Top 10 Co-Authors
Anne Durnez
Rene Westhovens
Veerle Taelman
Els Van Essche
Rik Joos
Patrick Verschueren
Johan Joly
Johan Vanhoof
Jan Lenaerts
Kristien Van der Elst
Published In
Eur J Appl Physiol
Acta Orthop Belg
Arthritis Res Ther
RMD Open
Ann Rheum Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Interleukin 6 inhibition in refractory antisynthetase syndrome: case-based literature review
Driesen A, Vulsteke J, Corluy L, Severi S, De Crem N, Dubbeldam A, et al.
Acta Clin Belg . 2025 Mar; 79(5):368-376. PMID: 40053413
Introduction: Antisynthetase syndrome (ASyS) is a rare idiopathic inflammatory myopathy (IIM), characterised by the presence of anti-aminoacyl tRNA synthetase antibodies. Significant clinical heterogeneity often results in delayed or missed diagnoses....
2.
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial
Bertrand D, Joly J, Neerinckx B, Durez P, Lenaerts J, Joos R, et al.
RMD Open . 2024 Aug; 10(3). PMID: 39117445
Objectives: To investigate if patients with early rheumatoid arthritis responding insufficiently to initial methotrexate (MTX) and bridging glucocorticoids (GCs) could benefit from early but temporary etanercept introduction as a second...
3.
Chronic Mycobacterium kansasii tenosynovitis in an immunocompromised host : case report
Lemmens L, Beek N, Corluy L, Verfaillie S
Acta Orthop Belg . 2021 Apr; 86(4):621-623. PMID: 33861908
Mycobacteriuim kansasii is a nontuberculous atypical mycobacterium which typically causes respiratory infections. Localized extrapulmonary diseases, such as tenosynovitis or arthritis are rarely seen in the immunocompetent population (1) . We...
4.
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic...
Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al.
Ann Rheum Dis . 2016 Jul; 76(3):511-520. PMID: 27432356
Objectives: Combining disease-modifying antirheumatic drugs (DMARDs) with glucocorticoids (GCs) is an effective treatment strategy for early rheumatoid arthritis (ERA), yet the ideal schedule and feasibility in daily practice are debated....
5.
Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial
Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al.
Arthritis Res Ther . 2015 Apr; 17:97. PMID: 25889222
Introduction: Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids...
6.
Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients
Hansen D, Dendale P, Beelen M, Jonkers R, Mullens A, Corluy L, et al.
Eur J Appl Physiol . 2010 Feb; 109(3):397-404. PMID: 20131064
Elevated plasma free fatty acid (FFA), inflammatory marker, and altered adipokine concentrations have been observed in obese type 2 diabetes patients. It remains unclear whether these altered plasma concentrations are...